Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout.
Belite Bio, Inc was founded in 2016 and is based in San Diego, California.
Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 17, 25 | -0.32 Decreased by -28.00% | -0.31 Decreased by -4.07% |
| Nov 12, 24 | -0.28 Increased by +30.00% | -0.30 Increased by +6.67% |
| Aug 12, 24 | -0.31 Decreased by -19.23% | -0.26 Decreased by -19.23% |
| May 13, 24 | -0.27 Increased by +18.18% | -0.28 Increased by +3.57% |
| Mar 11, 24 | -0.25 Increased by +32.43% | -0.30 Increased by +16.67% |
| Nov 13, 23 | -0.40 Decreased by -263.64% | -0.32 Decreased by -25.00% |
| Aug 8, 23 | -0.26 Decreased by -225.00% | -0.30 Increased by +13.33% |
| May 10, 23 | -0.33 Increased by +17.50% | -0.20 Decreased by -65.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -10.10 M Decreased by -44.47% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -8.68 M Increased by +20.63% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -9.49 M Decreased by -39.37% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.49 M Decreased by -37.69% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -6.99 M Decreased by -3.05% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.94 M Decreased by -355.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -6.81 M Decreased by -199.30% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -6.89 M Decreased by -534.31% | Decreased by N/A% Decreased by N/A% |